# Sbno2-mediated tissue-resident alveolar macrophages: a novel therapeutic axis for sepsis-induced acute lung injury

## TL;DR

This study identifies Sbno2-expressing alveolar macrophages as key players in lung repair during sepsis-induced lung injury, suggesting a new treatment approach.

## Contribution

The study reveals Sbno2-expressing tissue-resident alveolar macrophages as a novel therapeutic target for sepsis-induced acute lung injury.

## Key findings

- Sbno2-expressing alveolar macrophages promote alveolar epithelial cell regeneration and barrier function.
- Recombinant Sbno2 administration in a mouse model reduced lung injury and restored barrier function.
- Knockout of Sbno2 impaired alveolar epithelial cell proliferation and lung barrier integrity.

## Abstract

Sepsis-induced acute lung injury (ALI) is a critical clinical condition characterized by severe inflammation and alveolar epithelial barrier disruption, with limited effective treatments. Our study investigates the role of Sbno2-expressing tissue-resident alveolar macrophages (TR-AMs) in promoting alveolar epithelial cell (AEC) regeneration and barrier function in sepsis-induced ALI. Utilizing single-cell RNA sequencing (scRNA-seq), we identified significant upregulation of Sbno2 in TR-AMs, which correlated with enhanced AEC proliferation and reduced apoptosis. Functional assays demonstrated that Sbno2-expressing TR-AMs substantially supported alveolar structure regeneration in both in vitro and in vivo models. Knockout of Sbno2 in TR-AMs impaired AEC proliferation and compromised lung barrier integrity. Therapeutic administration of recombinant Sbno2 (rSbno2) in a sepsis-induced ALI mouse model alleviated lung injury, promoted AEC proliferation, and restored barrier function, highlighting Sbno2 as a potential therapeutic target for ALI. These findings provide novel insights into the molecular mechanisms of lung repair in sepsis-induced ALI and suggest that enhancing Sbno2 expression in TR-AMs could be a promising strategy for improving outcomes in patients with ALI.